IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31

Immunovant, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$27.62+0.89 (+3.33%)

Close on Oct 19, 2026

Market cap: $5.68B
P/E (TTM): –
Dividend yield: –

Immunovant, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31
Research & Development	457	361	213	160	102	69	48	26
General & Administrative	76	77	57	48	54	40	18	2.69
Operating Expenses	533	438	283	218	156	108	66	28
Interest Expense	–	–	–	–	–	0	0.63	–
Other Non-Operating Income	2.18	0.47	-1.01	-0.25	-0.78	0.33	0.41	-0.16
Gain (Loss) on Sale of Assets	–	–	–	–	–	0	-0.01	–
Pretax Income	-505	-413	-259	-211	-157	-108	-66	-29
Income Tax Expense	0.22	0.89	0.57	0.01	-0.08	-0.36	0.10	0.02
Net Income	-506	-414	-259	-211	-157	-107	-66	-29
EPS (Basic)(per share)	-2.77	-2.73	-1.88	-1.71	-1.43	-1.22	-1.54	-1.29
EPS (Diluted)(per share)	-2.77	-2.73	-1.88	-1.71	-1.43	-1.22	-1.54	-1.29
Shares Outstanding (Basic, Weighted)(shares)	182	152	138	123	110	88	43	22
Shares Outstanding (Diluted, Weighted)(shares)	182	152	138	123	110	88	43	22
Net Interest Income	–	–	25	7.58	0	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -64.8%

Financial strength

Current ratio: 7.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 681.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 7.72
Dividend yield: –